Babatin Mohamed, Lee Samuel S, Pollak P Timothy
Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
Curr Vasc Pharmacol. 2008 Jul;6(3):228-36. doi: 10.2174/157016108784912019.
Potential hepatotoxicity related to amiodarone therapy is often a concern when deciding whether to initiate or continue treatment with this medication. While mostly associated with long-term oral administration of the drug, toxicity has also been reported early during intravenous administration and months after discontinuation of therapy. In the majority of patients, it is discovered incidentally during routine testing of liver biochemistry and rarely do the hepatic effects develop into symptomatic liver injury or failure. Despite the widespread use of amiodarone, prospective clinical studies have been sparse and there has been little consensus among experts in the field regarding optimum monitoring for adverse effects in patients receiving this drug. In order to examine the current state of knowledge surrounding the incidence, pathogenesis and mechanism of liver effects associated with amiodarone, the existing literature was reviewed, with particular emphasis on clinical recommendations for monitoring.
在决定是否开始或继续使用胺碘酮治疗时，与胺碘酮治疗相关的潜在肝毒性常常令人担忧。虽然毒性大多与长期口服该药有关，但在静脉给药早期以及停药数月后也有相关报道。在大多数患者中，肝毒性是在常规肝功能检查时偶然发现的，肝效应很少发展为有症状的肝损伤或肝衰竭。尽管胺碘酮被广泛使用，但前瞻性临床研究却很稀少，该领域的专家对于接受该药治疗患者不良反应的最佳监测方法也几乎没有达成共识。为了研究围绕胺碘酮相关肝效应的发生率、发病机制和机制的现有知识状况，我们回顾了现有文献，特别强调了监测的临床建议。
